Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

797.70 +42.70 (+5.66%)
Streaming Delayed Price Updated: 11:09 AM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
99 100 Next >
Rally Rockets: 3 Stocks Benefitting From the Market’s Unstoppable Surge
Don't miss out on profit potential of these stocks to buy. Explore three top stocks poised to unlock gains in a surging market. 
Via InvestorPlace
Evaluating Eli Lilly and Co Against Peers In Pharmaceuticals Industry
Via Benzinga
Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries
Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries 
Via News Direct
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
Could Amgen be the next stock to soar due to a GLP-1 drug? 
Via The Motley Fool
3 Stocks To Buy Following Positive Earnings Results
Total earnings for the S&P 500 members that have reported Q1 results are up +4.8% from the same period last year on +4.1% higher revenues. The earnings growth pace reflects an acceleration relative to... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Is Eli Lilly's Latest Deal a Gamechanger?
Eli Lilly just took a page out of Novo Nordisk's book. 
Via The Motley Fool
1 No-Brainer Growth Stock to Buy and Hold
It's hard to bet against this high-flying stock. 
Via The Motley Fool
Eli Lilly's Weekly Insulin Dose On Par With Commonly Used Daily Doses, Phase 3 Studies Show
Eli Lilly phase 3 trials reveal once-weekly insulin efsitora as a non-inferior alternative to daily basal insulins for type 2 diabetes. 
Via Benzinga
The Dividend Investor’s Playbook: 3 Stocks for Consistent Cash Flow in 2024
Dive into dividend stocks to buy, featuring Walmart's robust earnings and Eli Lilly's advances in pharmaceuticals and WMT's stock split. 
Via InvestorPlace
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
These 2 No-Brainer Growth Stocks Are Breaking New Ground
The future keeps getting brighter for these companies. 
Via The Motley Fool
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics. 
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Wall Street Favorites: 3 Growth Stocks With Strong Buy Ratings for May 2024
It's not too late to take a position in these growth names, each of which should see their share prices rise in the near-term. 
Via InvestorPlace
No Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk Confirms
Novo Nordisk confirms there is no anticipated shortage of Wegovy in Denmark, despite prior warnings from the Danish Medicines Agency about limited supplies. The company addresses high demand and... 
Via Benzinga
Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound
Eli Lilly has settled with Totality Medispa over counterfeit Mounjaro and Zepbound sales. The spa will pay damages and cease using Lilly branding. Corrective measures include compliance with federal... 
Via Benzinga
These 2 Words Explain Why Eli Lilly Stock Is a Buy Right Now
Its latest medicines for obesity and type 2 diabetes are selling rapidly. 
Via The Motley Fool
2 Top Pharma Stocks That Just Keep Getting Better and Better
Both of these businesses are finding traction in a pair of major markets. 
Via The Motley Fool
Biotech Behemoths: 3 Giants Set to Dominate the Health Scene
The biotech behemoths stand out as compelling and exciting options for investors seeking steady long-term growth. 
Via InvestorPlace
3 Magnificent Stocks That Are Passive Income Machines
These three companies have track records that should please investors. 
Via The Motley Fool
Pfizer Follows Eli Lilly's Footsteps To Sell Medicines Directly To Patients
Pfizer seeks to expands its reach with 'Pfizer for All,' offering direct-to-consumer medical services, including COVID treatments & telehealth. 
Via Benzinga
Exposures COVID-19
How Viking Therapeutics Stock Could 30x
This mid-cap biopharma may one day be a titan of the industry. 
Via The Motley Fool
The Must-Watch List: 3 Stocks to Snap Up as Soon as They Hit Bargain Territory
These three companies could soon be the next bargain stocks to buy as the market adjusts to their developing situations. 
Via InvestorPlace
Healthcare And Biotech Investing 101: What You Need To Know.
Healthcare as a sector represents only about 12% of the S&P 500. If you want to overweight healthcare as a sector you need to add equities. Healthcare is usually a defensive sector because of... 
Via Talk Markets
Topics Stocks
Exposures US Equities
MarketBeat Week in Review – 5/6 - 5/10
Sell in May, then go away got pushed to the side this week, but the bearish sentiment could return when investors get the latest read on inflation next week. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
These pharmaceutical companies are top-notch dividend growth stocks for the future. 
Via The Motley Fool
SPDR ETF Report For Friday, May 10
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day that ended, Friday, May 10. 
Via Talk Markets
Topics ETFs
Highest And Lowest Price To Sales (P/S) Ratios
In the S&P 1500 there are just under 1,175 stocks that have positive next-year EPS estimates and trailing 12-month revenues of more than $1 billion. 
Via Talk Markets
Topics Stocks
Exposures US Equities
3 Biotech Stocks to Sell in May Before They Crash & Burn
Discover essential insights on biotech stocks to sell in May to navigate market volatility and safeguard your investment portfolio. 
Via InvestorPlace
Can Weight Loss Companies Fuel Gains In Your Stock Portfolio?
Analysts predict the weight loss drug market could reach $100 billion by the end of the decade, with millions of patients potentially using these medications. However, challenges remain. 
Via Talk Markets
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.